Chief Medical Officer Jared Gollob Sells 46,137 Shares of Kymera Therapeutics Inc [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
to a recent SEC Filing . Kymera Therapeutics Inc is a biotechnology company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own process of protein degradation. Warning! GuruFocus has detected 5 Warning Sign with KYMR. Over the past year, the insider has sold a total of 46,137 shares and has not made any purchases of the company's stock. Insider Trends The transaction history for insiders at Kymera Therapeutics Inc indicates a trend of more insider selling than buying over the past year. There has been a total of 1 insider buy and 4 insider sells during this period. Valuation On the date of the insider's recent sale, shares of Kymera Therapeutics Inc were trading at $35.5, resulting in a market cap of $2.209 billion. The stock's price-to-GF-Value ratio stands at 1.05, with a GF Value of $33.97, indicating that Kymera Therapeutics Inc is Fairly Valued based on its GF Value. The G
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewswire
- Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2GlobeNewswire
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $53.00 price target on the stock.MarketBeat
- Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingGlobeNewswire
KYMR
Earnings
- 5/2/24 - Beat
KYMR
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/24/24 - Form ARS
- KYMR's page on the SEC website